2021
DOI: 10.1016/j.ecl.2021.05.005
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of Microvascular Complications of Diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
31
0
7

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(40 citation statements)
references
References 53 publications
2
31
0
7
Order By: Relevance
“…The onset and progression of diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) can be delayed by intensive glycemic control. This finding has been shown in type 1 DM, but the current evidence in type 2 DM is weak[ 30 - 32 ]. However, no specific therapeutic agent or approach other than glycemic control can modify the progression of microvascular complications[ 7 , 10 ].…”
Section: Current Evidence For Preventionsupporting
confidence: 53%
“…The onset and progression of diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) can be delayed by intensive glycemic control. This finding has been shown in type 1 DM, but the current evidence in type 2 DM is weak[ 30 - 32 ]. However, no specific therapeutic agent or approach other than glycemic control can modify the progression of microvascular complications[ 7 , 10 ].…”
Section: Current Evidence For Preventionsupporting
confidence: 53%
“…Serious complications affecting the nerves and blood vessels can occur as the course of diabetes progresses. Specifically, cardiovascular disease is one of the most common clinical complications of diabetes [ 1 ]. Elevated blood sugar levels can lead to lipid metabolism problems among vascular endothelial cells and cardiomyocytes and the accumulation of local inflammatory factors.…”
Section: Introductionmentioning
confidence: 99%
“…The largest cluster for co-cited reference was labeled as “diabetes complications.” The most relevant citer in the cluster was Winston Crasto. He has discussed the microvascular complications of diabetes, including DN, DR, and diabetic neuropathy, and provides best practice clinical care recommendations to guide health care professionals to better manage people with these conditions ( Crasto et al, 2021 ). Additionally, cluster #2 was labeled as “methylenetetrahydrofolate reductase (MTHFR)”.…”
Section: Discussionmentioning
confidence: 99%